• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Moderna Set to Join S&P 500

    7/15/21 7:01:00 PM ET
    $SPGI
    $ALXN
    $AZN
    $MRNA
    Finance: Consumer Services
    Finance
    Major Pharmaceuticals
    Health Care
    Get the next $SPGI alert in real time by email

    NEW YORK, July 15, 2021 /PRNewswire/ -- Moderna Inc. (NASD:MRNA) will replace Alexion Pharmaceuticals Inc. (NASD:ALXN) in the S&P 500 effective prior to the opening of trading on Wednesday, July 21. AstraZeneca Plc (LSE:AZN; NASD:AZN) is acquiring Alexion Pharmaceuticals in a deal expected to be completed soon pending final closing conditions.

    Following is a summary of the changes that will take place prior to the open of trading on the effective date:

    Effective Date

    Index Name      

    Action

    Company Name

    Ticker

    GICS Sector

    July 21, 2021

    S&P 500

    Addition

    Moderna

    MRNA

    Health Care



    S&P 500

    Deletion

    Alexion Pharmaceuticals

    ALXN

    Health Care

    For more information about S&P Dow Jones Indices, please visit www.spdji.com

    ABOUT S&P DOW JONES INDICES

    S&P Dow Jones Indices is the largest global resource for essential index-based concepts, data and research, and home to iconic financial market indicators, such as the S&P 500® and the Dow Jones Industrial Average®. More assets are invested in products based on our indices than products based on indices from any other provider in the world. Since Charles Dow invented the first index in 1884, S&P DJI has been innovating and developing indices across the spectrum of asset classes helping to define the way investors measure and trade the markets.

    S&P Dow Jones Indices is a division of S&P Global (NYSE:SPGI), which provides essential intelligence for individuals, companies, and governments to make decisions with confidence. For more information, visit www.spdji.com.

    FOR MORE INFORMATION:

    S&P Dow Jones Indices

    [email protected]

    Media Inquiries

    [email protected]

    Cision View original content:https://www.prnewswire.com/news-releases/moderna-set-to-join-sp-500-301335329.html

    SOURCE S&P Dow Jones Indices

    Get the next $SPGI alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SPGI
    $ALXN
    $AZN
    $MRNA

    CompanyDatePrice TargetRatingAnalyst
    S&P Global Inc.
    $SPGI
    10/1/2025$540.00Buy
    Seaport Research Partners
    AstraZeneca PLC
    $AZN
    4/15/2025$75.00Outperform
    Exane BNP Paribas
    S&P Global Inc.
    $SPGI
    4/10/2025$600.00Buy
    BofA Securities
    Moderna Inc.
    $MRNA
    3/13/2025$40.00Neutral
    Citigroup
    S&P Global Inc.
    $SPGI
    3/12/2025$599.00Outperform
    Mizuho
    Moderna Inc.
    $MRNA
    2/18/2025$111.00 → $45.00Overweight → Equal Weight
    Barclays
    AstraZeneca PLC
    $AZN
    2/13/2025Neutral → Buy
    UBS
    AstraZeneca PLC
    $AZN
    2/12/2025Overweight
    Morgan Stanley
    More analyst ratings

    $SPGI
    $ALXN
    $AZN
    $MRNA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Seaport Research Partners initiated coverage on S&P Global with a new price target

    Seaport Research Partners initiated coverage of S&P Global with a rating of Buy and set a new price target of $540.00

    10/1/25 9:39:03 AM ET
    $SPGI
    Finance: Consumer Services
    Finance

    Exane BNP Paribas initiated coverage on AstraZeneca with a new price target

    Exane BNP Paribas initiated coverage of AstraZeneca with a rating of Outperform and set a new price target of $75.00

    4/15/25 12:40:56 PM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BofA Securities resumed coverage on S&P Global with a new price target

    BofA Securities resumed coverage of S&P Global with a rating of Buy and set a new price target of $600.00

    4/10/25 8:19:38 AM ET
    $SPGI
    Finance: Consumer Services
    Finance

    $SPGI
    $ALXN
    $AZN
    $MRNA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    S&P Dow Jones Indices Reports U.S. Common Indicated Dividend Payments Increase of $10.6 Billion in Q3 2025 as Dividend Growth Continues to Be Slow

    Q3 2025 U.S. common dividend increases were $14.0 billion, up 43.0% from $9.8 billion in Q2 2025 and down 0.7% from $14.1 billion in Q3 2024.Q3 2025 U.S. common dividend decreases were $3.4 billion, up 46.1% from $2.3 billion in Q2 2025 and down 25.2% from $4.6 billion in Q3 2024.Q3 2025 net indicated dividend rate change increased $10.6 billion. For the 12-months ending September 2025 U.S. common dividend increases were $57.5 billion, down 23.1% from the 12-month September 2024 period's $74.7 billion; decreases were down 36.4% to $12.4 billion compared to $19.5 billion for the prior 12-month period.The net 12-month September 2025 indicated dividend increase was $45.1 billion compared to $44

    10/10/25 9:00:00 AM ET
    $SPGI
    Finance: Consumer Services
    Finance

    CHINA DRIVES STRONGEST GROWTH IN GLOBAL FACTORY PURCHASING SINCE MID-2022, WHILE NORTH AMERICAN MANUFACTURERS COOL IN SEPTEMBER: GEP GLOBAL SUPPLY CHAIN VOLATILITY INDEX

    Chinese manufacturers sharply increased purchasing in September, propelling Asia's supply chains to their busiest level since June 2022.In contrast, tariff-related disruptions and a softer economic outlook curbed North American manufacturing activity.Europe's recovery remains sluggish, with supply chains operating at their weakest since March.CLARK, N.J., Oct. 10, 2025 /PRNewswire/ -- GEP Global Supply Chain Volatility Index — a leading indicator tracking demand conditions, shortages, transportation costs, inventories, and backlogs based on a monthly survey of 27,000 businesses — was little changed in September (-0.38 vs -0.39 in August), indicating that global supply chains are operating be

    10/10/25 8:06:00 AM ET
    $SPGI
    Finance: Consumer Services
    Finance

    S&P Global and CME Group Complete Sale of OSTTRA to KKR

    NEW YORK, Oct. 10, 2025 /PRNewswire/ -- S&P Global (NYSE:SPGI) and CME Group today announced that they have completed the sale of OSTTRA to KKR, a leading global investment firm. The terms of the deal for OSTTRA equaled total enterprise value at $3.1 billion, which will be divided evenly between S&P Global and CME Group pursuant to their 50/50 joint venture. Established in 2021 as a joint venture between CME Group and S&P Global, OSTTRA serves the global financial ecosystem with a comprehensive suite of critical post-trade offerings across interest rates, FX, credit and equity

    10/10/25 7:00:00 AM ET
    $SPGI
    Finance: Consumer Services
    Finance

    $SPGI
    $ALXN
    $AZN
    $MRNA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    November 30, 2020 - Coronavirus (COVID-19) Update: FDA Announces Advisory Committee Meeting to Discuss Second COVID-19 Vaccine Candidate

    For Immediate Release: November 30, 2020 The U.S. Food and Drug Administration has scheduled a meeting of its Vaccines and Related Biological Products Advisory Committee (VRBPAC) on Dec. 17 to discuss the request for emergency use authorization (EUA) for a COVID-19 vaccine from Moderna, Inc. “In keeping with the FDA’s commitment to ensuring full transparency, dialogue and efficiency, the Vaccines and Related Biological Products Advisory Comm

    11/30/20 5:12:14 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SPGI
    $ALXN
    $AZN
    $MRNA
    SEC Filings

    View All

    SEC Form SC TO-C filed by Moderna Inc.

    SC TO-C - Moderna, Inc. (0001682852) (Subject)

    10/10/25 10:42:54 AM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 6-K filed by AstraZeneca PLC

    6-K - ASTRAZENECA PLC (0000901832) (Filer)

    10/7/25 6:30:06 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by AstraZeneca PLC

    6-K - ASTRAZENECA PLC (0000901832) (Filer)

    10/6/25 7:18:50 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SPGI
    $ALXN
    $AZN
    $MRNA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Mock James M covered exercise/tax liability with 703 shares and converted options into 1,453 shares, increasing direct ownership by 4% to 18,259 units (SEC Form 4)

    4 - Moderna, Inc. (0001682852) (Issuer)

    10/6/25 4:23:23 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Hussain Abbas converted options into 1,439 shares, increasing direct ownership by 248% to 2,019 units (SEC Form 4)

    4 - Moderna, Inc. (0001682852) (Issuer)

    10/6/25 4:14:33 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    EVP, Chief People Officer Ganesan Girish exercised 181 shares at a strike of $481.67 and covered exercise/tax liability with 73 shares, increasing direct ownership by 8% to 1,383 units (SEC Form 4)

    4 - S&P Global Inc. (0000064040) (Issuer)

    10/3/25 4:02:20 PM ET
    $SPGI
    Finance: Consumer Services
    Finance

    $SPGI
    $ALXN
    $AZN
    $MRNA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Bancel Stephane bought $5,004,318 worth of shares (160,314 units at $31.22) (SEC Form 4)

    4 - Moderna, Inc. (0001682852) (Issuer)

    3/4/25 4:27:16 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Sagan Paul bought $1,004,251 worth of shares (31,620 units at $31.76) (SEC Form 4)

    4 - Moderna, Inc. (0001682852) (Issuer)

    3/4/25 4:24:36 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Jacoby Rebecca bought $8,971 worth of shares (69 units at $130.01), increasing direct ownership by 17% to 469 units (SEC Form 4)

    4 - S&P Global Inc. (0000064040) (Issuer)

    6/17/24 4:04:40 PM ET
    $SPGI
    Finance: Consumer Services
    Finance

    $SPGI
    $ALXN
    $AZN
    $MRNA
    Financials

    Live finance-specific insights

    View All

    S&P Dow Jones Indices Reports U.S. Common Indicated Dividend Payments Increase of $10.6 Billion in Q3 2025 as Dividend Growth Continues to Be Slow

    Q3 2025 U.S. common dividend increases were $14.0 billion, up 43.0% from $9.8 billion in Q2 2025 and down 0.7% from $14.1 billion in Q3 2024.Q3 2025 U.S. common dividend decreases were $3.4 billion, up 46.1% from $2.3 billion in Q2 2025 and down 25.2% from $4.6 billion in Q3 2024.Q3 2025 net indicated dividend rate change increased $10.6 billion. For the 12-months ending September 2025 U.S. common dividend increases were $57.5 billion, down 23.1% from the 12-month September 2024 period's $74.7 billion; decreases were down 36.4% to $12.4 billion compared to $19.5 billion for the prior 12-month period.The net 12-month September 2025 indicated dividend increase was $45.1 billion compared to $44

    10/10/25 9:00:00 AM ET
    $SPGI
    Finance: Consumer Services
    Finance

    Baxdrostat met the primary endpoint in Bax24 Phase III trial in patients with resistant hypertension

    Baxdrostat demonstrated a statistically significant and highly clinically meaningful reduction in 24-hour ambulatory systolic blood pressure compared with placebo Positive high-level results from the Bax24 Phase III trial showed baxdrostat demonstrated a statistically significant and highly clinically meaningful reduction in ambulatory 24-hour average systolic blood pressure (SBP) compared with placebo at 12 weeks. Efficacy was observed throughout the 24-hour period, including early morning, when patients with hypertension are at a higher risk of cardiovascular events.1-3 Patients with treatment-resistant hypertension (rHTN) received baxdrostat 2mg or placebo on top of standard of care.

    10/7/25 7:00:00 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    S&P Global Schedules Third Quarter 2025 Earnings Announcement and Conference Call for Thursday, October 30, 2025

    NEW YORK, Oct. 2, 2025 /PRNewswire/ -- S&P Global's (NYSE:SPGI) third quarter 2025 results will be issued on Thursday, October 30, 2025 via news release at approximately 7:15 a.m. Eastern Daylight Time. The news release will be available at www.spglobal.com. Martina Cheung, President and CEO; Eric Aboaf, Chief Financial Officer; and Mark Grant, Senior Vice President, Investor Relations and Treasurer, will host a conference call and webcast at 8:30 a.m. Eastern Daylight Time on October 30, 2025 to discuss the Company's third quarter 2025 financial results. The presentation is open to all interested parties and may include forward-looking information. The presenters' slides, supplemental deck

    10/2/25 4:00:00 PM ET
    $SPGI
    Finance: Consumer Services
    Finance

    $SPGI
    $ALXN
    $AZN
    $MRNA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Moderna Inc. (Amendment)

    SC 13G/A - Moderna, Inc. (0001682852) (Subject)

    4/10/24 2:03:52 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by S&P Global Inc. (Amendment)

    SC 13G/A - S&P Global Inc. (0000064040) (Subject)

    2/13/24 5:13:53 PM ET
    $SPGI
    Finance: Consumer Services
    Finance

    SEC Form SC 13G/A filed by Moderna Inc. (Amendment)

    SC 13G/A - Moderna, Inc. (0001682852) (Subject)

    2/7/24 8:42:56 AM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SPGI
    $ALXN
    $AZN
    $MRNA
    Leadership Updates

    Live Leadership Updates

    View All

    Bentley Systems Set to Join S&P MidCap 400 and Western Union to Join S&P SmallCap 600

    NEW YORK, Oct. 1, 2025 /PRNewswire/ -- Bentley Systems Inc. (NASD: BSY) will replace Western Union Co. (NYSE:WU) in the S&P MidCap 400, and Western Union will replace Mr. Cooper Group Inc. (NASD: COOP) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, October 6. Rocket Companies Inc. (NYSE:RKT) acquired Mr. Cooper Group in a deal that closed today, October 1. Western Union's market capitalization is more representative of the small-cap market space. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name        Action Company Name Ticker GICS Sector October 6, 2025   S&P MidCap

    10/1/25 6:03:00 PM ET
    $BSY
    $RKT
    $SPGI
    Computer Software: Prepackaged Software
    Technology
    Finance: Consumer Services
    Finance

    Carbon Data Open Protocol (CDOP) Coalition Unveils Open-Source Data Model at Climate Week NYC to Facilitate and Scale Carbon Markets

    37 organizations including Isometric, Verra, South Pole, and Kita commit to continue supporting the adoption and development of the Carbon Data Open Protocol (CDOP) Version 1.0 Open-source data schema for project location, details & approach addresses carbon market fragmentationDeveloped in alignment with, and building upon, other data standardization initiatives, including the G20-led Common Carbon Credit Data Model (CCCDM), the CAD Trust, and the UNFCCC (relating to Article 6)NEW YORK, Sept. 23, 2025 /PRNewswire/ -- Today at Climate Week NYC a growing coalition of carbon market participants announced the release of Version 1.0 of the Carbon Data Open Protocol (CDOP) structure to help facil

    9/23/25 7:00:00 AM ET
    $SPGI
    Finance: Consumer Services
    Finance

    ACM Research Set to Join S&P SmallCap 600

    NEW YORK, Sept. 22, 2025 /PRNewswire/ -- ACM Research Inc. (NASD: ACMR) will replace WK Kellogg Co. (NYSE:KLG) in the S&P SmallCap 600 effective prior to the opening of trading on Friday, September 26. The Ferrero Group is acquiring WK Kellogg in a deal expected to close soon, pending final closing conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector Sept 26, 2025 S&P SmallCap 600 Addition ACM Research ACMR Information Technology Sept 26, 2025 S&P SmallCap 600 Deletion WK Kellogg KLG Consumer Staples ABOUT S&P DOW JONES INDICES S&P Dow Jones Indices i

    9/22/25 6:16:00 PM ET
    $ACMR
    $KLG
    $SPGI
    Industrial Machinery/Components
    Technology
    Packaged Foods
    Consumer Staples